LB

Longboard Pharmaceuticals IncNASDAQ LBPH Stock Report

Last reporting period 30 Sep, 2023

Updated 15 Nov, 2024

Last price

Market cap $B

1.27

Small

Exchange

XNAS - Nasdaq

LBPH Stock Analysis

LB

Uncovered

Longboard Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

1.27

Dividend yield

Shares outstanding

22.965 B

Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for neurological diseases. The company is headquartered in La Jolla, California and currently employs 33 full-time employees. The company went IPO on 2021-03-12. The firm is focused on developing medicines for neurological diseases. Its pipelines includes LP352, LP143 and LP659. LP352 is an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype (5-HT2c) superagonist for the treatment of developmental and epileptic encephalopathies (DEEs), including Dravet syndrome and Lennox-Gastaut syndrome, among others. LP143 is a centrally acting, full cannabinoid type 2 receptor (CB2) agonist in investigational new drug application (IND)-enabling studies for neurodegenerative diseases associated with neuroinflammation caused by microglial activation, including amyotrophic lateral sclerosis (ALS). LP659 is a centrally acting, sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 (S1P1,5) modulator in IND-enabling studies for central nervous system (CNS) neuroinflammatory diseases.

View Section: Eyestock Rating